GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » ANI Pharmaceuticals Inc (FRA:BSFA) » Definitions » 14-Day RSI

ANI Pharmaceuticals (FRA:BSFA) 14-Day RSI : 56.65 (As of Dec. 12, 2024)


View and export this data going back to 2004. Start your Free Trial

What is ANI Pharmaceuticals 14-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2024-12-12), ANI Pharmaceuticals's 14-Day RSI is 56.65.

The industry rank for ANI Pharmaceuticals's 14-Day RSI or its related term are showing as below:

FRA:BSFA's 14-Day RSI is ranked worse than
69.25% of 1096 companies
in the Drug Manufacturers industry
Industry Median: 49.19 vs FRA:BSFA: 56.65

Competitive Comparison of ANI Pharmaceuticals's 14-Day RSI

For the Drug Manufacturers - Specialty & Generic subindustry, ANI Pharmaceuticals's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ANI Pharmaceuticals's 14-Day RSI Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, ANI Pharmaceuticals's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where ANI Pharmaceuticals's 14-Day RSI falls into.



ANI Pharmaceuticals  (FRA:BSFA) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ANI Pharmaceuticals  (FRA:BSFA) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.


ANI Pharmaceuticals 14-Day RSI Related Terms

Thank you for viewing the detailed overview of ANI Pharmaceuticals's 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


ANI Pharmaceuticals Business Description

Traded in Other Exchanges
Address
210 Main Street West, Baudette, MN, USA, 56623
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.

ANI Pharmaceuticals Headlines

No Headlines